# Tocilizumab in COVID-19 Lahore General Hospital

> **NCT04560205** · PHASE1 · UNKNOWN · sponsor: **Lahore General Hospital** · enrollment: 50 (estimated)

## Conditions studied

- SARS-CoV Infection

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04560205
- **Lead sponsor:** Lahore General Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-01
- **Primary completion:** 2020-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04560205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04560205, "Tocilizumab in COVID-19 Lahore General Hospital". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04560205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*